{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:49:47Z","timestamp":1790873387694,"version":"4.1.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pembrolizumab-induced hypophysitis is a rare but clinically important immune-related adverse event. Its clinical features and long-term outcomes are not fully defined. This study aimed to summarize the clinical characteristics, management, and prognosis of pembrolizumab-associated hypophysitis to support early recognition and appropriate treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, EMBASE, Web of Science, WanFang Data, and CNKI were searched for reports of pembrolizumab-induced hypophysitis published up to Jan 31, 2026, using relevant keywords and Boolean operators. Eligible case reports and case series were screened, and patient-level data were extracted using a standardized form. Study quality was assessed with the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case Reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 22 patients were included. The median age was 66 years (range 39\u201385), with equal distribution between males and females. The median time to onset was 15 weeks (range 2\u201336), most frequently occurring within 11\u201320 weeks. Fatigue was the predominant symptom (86.4%), followed by nausea\/vomiting (54.5%), adrenal insufficiency manifestations (40.9%), hyponatremia (31.8%), and headache (27.3%). Median cortisol and ACTH levels were markedly reduced at 0.9 \u03bcg\/dL and 5.0 pg\/mL, respectively. Among patients with available pituitary MRI data, normal findings were observed in 50.0% of cases, whereas pituitary enlargement was present in 27.8%. Hormone replacement therapy, primarily hydrocortisone, was administered in 81.8% of cases. Clinical improvement occurred in 90.9% of patients; however, persistent endocrine dysfunction remained in 95.5%, with recovery of the hypothalamic\u2013pituitary axis documented in only one case. Rechallenge was performed in seven patients without recurrence in most cases. According to the WHO-UMC system, 86.4% of cases were classified as probable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pembrolizumab-induced hypophysitis typically presents subacutely with nonspecific symptoms and frequently exhibits normal imaging findings. Although clinical symptoms improve with prompt hormone replacement, permanent endocrine insufficiency is common. Early recognition and long-term endocrine follow-up are essential in affected patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1823373","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:42:12Z","timestamp":1781070132000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical characteristics, management, and prognosis of pembrolizumab-induced hypophysitis: retrospective analysis based on case reports"],"prefix":"10.3389","volume":"17","author":[{"given":"Jingjing","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, The Central Hospital of Xiangtan (The Affiliated Hospital of Hunan University)","place":["Xiangtan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Student Affairs, Hunan University of Medicine General Hospital","place":["Huaihua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, The Central Hospital of Xiangtan (The Affiliated Hospital of Hunan University)","place":["Xiangtan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Student Affairs, Hunan University of Medicine General Hospital","place":["Huaihua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01206-x","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00554-x","article-title":"Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: A special focus on nivolumab and pembrolizumab","volume":"23","author":"Malmberg","year":"2022","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2021.1835477","article-title":"Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel cell carcinoma: Safety and efficacy","volume":"20","author":"Marchand","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"25919","DOI":"10.1038\/s41598-024-75099-5","article-title":"Cardiovascular adverse events and immune-related adverse events associated with Pd-1\/Pd-L1 inhibitors for head and neck squamous cell carcinoma (Hnscc)","volume":"14","author":"Abulizi","year":"2024","journal-title":"Sci Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-Pd-1 and anti-Pd-L1 drugs: Systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"Bmj"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae067","article-title":"The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors","volume":"54","author":"Fukushima","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/03946320251326699","article-title":"Immune-related adverse events-pembrolizumab-induced colitis-the importance of early diagnosis and treatment: A case report and review of the literature","volume":"39","author":"Markovic","year":"2025","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (Iraes): Diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1530\/eje-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000001129","article-title":"Hypophysitis secondary to pembrolizumab: A case report and review of the literature","volume":"33","author":"Montero P\u00e9rez","year":"2022","journal-title":"Anticancer Drugs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luae200","article-title":"Pembrolizumab-induced thyroiditis, hypophysitis and adrenalitis: A case of triple endocrine dysfunction","volume":"2","author":"Rossi","year":"2024","journal-title":"JCEM Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1530\/eo-25-0046","article-title":"Adrenal crisis due to pembrolizumab-induced hypophysitis in a patient with triple-negative breast cancer","volume":"5","author":"Mohammed","year":"2025","journal-title":"Endocr Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4158\/accr-2019-0585","article-title":"A common pituitary autoantibody in two patients with immune checkpoint inhibitor-mediated hypophysitis: Zcchc8","volume":"6","author":"Leiter","year":"2020","journal-title":"AACE Clin Case Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.730","article-title":"Complete response in a patient with lung cancer suffering from three pembrolizumab-induced immune-related adverse events including retinal vasculitis","volume":"9","author":"Mimura","year":"2021","journal-title":"Respirol Case Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27763","article-title":"Exploring a new entity of single-agent pembrolizumab-associated hypophysitis","volume":"14","author":"Balti","year":"2022","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19726","article-title":"Immunotherapy: A case series","volume":"13","author":"Do","year":"2021","journal-title":"Cureus"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-019-0092-9","article-title":"Isolated\u00a0Acth deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: A case report","volume":"6","author":"Tanaka","year":"2020","journal-title":"Clin Diabetes Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/mjt.0000000000000832","article-title":"Immune checkpoint inhibitor-associated central adrenal insufficiency","volume":"26","author":"Mishra","year":"2019","journal-title":"Am J Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.12659\/ajcr.931639","article-title":"Isolated adrenocorticotropic hormone deficiency associated with severe hyperkalemia during pembrolizumab therapy in a patient with ureteral cancer and an ileal conduit: A case report and literature review","volume":"22","author":"Hinata","year":"2021","journal-title":"Am J Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0061","article-title":"Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: A new case and literature review","volume":"13","author":"O\u011fuz","year":"2021","journal-title":"Immunotherapy"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.91766","article-title":"Beyond the tumour: An endocrine pitfall of immunotherapy","volume":"17","author":"Than","year":"2025","journal-title":"Cureus"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220921543","article-title":"Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab","volume":"27","author":"Kethireddy","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luad135","article-title":"Nothing great comes without its risks: A rare case of pembrolizumab-induced hypophysitis","volume":"2","author":"Fernando","year":"2024","journal-title":"JCEM Case Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-254034","article-title":"Pd-1 inhibitor-induced thyroiditis and Acth deficiency","volume":"18","author":"Shah","year":"2025","journal-title":"BMJ Case Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.55729\/2000-9666.1173","article-title":"Pembrolizumab-induced broken heart syndrome, pneumonitis, and hypophysitis occurring concurrently; a deadly triad","volume":"13","author":"Khan","year":"2023","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.82940","article-title":"Pembrolizumab-induced hypophysitis in the setting of renal cell carcinoma","volume":"17","author":"Ogbodu","year":"2025","journal-title":"Cureus"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.84880","article-title":"Pembrolizumab-induced hypothyroidism and diabetes mellitus: A rare case presentation post-treatment","volume":"17","author":"Perera","year":"2025","journal-title":"Cureus"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15465","article-title":"Pembrolizumab-induced hypophysitis with isolated adrenocorticotropic hormone (Acth) deficiency: A rare immune-mediated adverse event","volume":"13","author":"Doodnauth","year":"2021","journal-title":"Cureus"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.82701","article-title":"Pembrolizumab-induced hypophysitis: A rare immune-related adverse event in a patient with metastatic non-small cell lung cancer","volume":"17","author":"Al Heyasat","year":"2025","journal-title":"Cureus"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2217\/cns-2023-0005","article-title":"Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: A case report","volume":"12","author":"Webb","year":"2023","journal-title":"CNS Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/reports6020018","article-title":"Secondary adrenal insufficiency due to isolated Acth deficiency induced by pembrolizumab: A report of two cases of uterine endometrial cancer","volume":"6","author":"Onoyama","year":"2023","journal-title":"Rep (MDPI)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-024-03647-z","article-title":"Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis","volume":"80","author":"Oliveira","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"B38","first-page":"3669","article-title":"Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome","volume-title":"Cancer Immunol Immunother","author":"Kanie","year":"2021"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101668","article-title":"Immune checkpoint inhibitor-related hypophysitis","volume":"36","author":"Mizukoshi","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/cancers17030436","article-title":"Immunotherapy-related hypophysitis: A narrative review","volume":"17","author":"Di Stasi","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.7098","article-title":"Hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: Diagnostic challenges and link with survival","volume":"21","author":"Johnson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2025-341","article-title":"Successful rechallenge of immune checkpoint inhibitors after severe immune-related hepatitis, thyroiditis and hypophysitis in Tmb-high Nsclc: A case report","volume":"14","author":"Zhou","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.836859","article-title":"Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function","volume":"12","author":"Jessel","year":"2022","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1823373\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:42:13Z","timestamp":1781070133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1823373\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2026.1823373"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1823373","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1823373"}}